Novartis' Arzerra combination significantly raises progression-free survival versus chlorambucil

15 April 2015
novartis-basel-big

Treatment with Arzerra (ofatumumab) from Swiss pharma giant Novartis (NOVN: VX) plus chlorambucil resulted in a statistically significant improvement in progression-free survival versus chlorambucil alone in a section of leukemia patients.

Phase III data published in medical journal The Lancet showed that Arzerra and chlorambucil improved median progression-free survival by 71% in treatment-naive patients with chronic lymphocytic leukemia for whom fludarabine-based therapy was considered inappropriate.

Already marketed Arzerra was acquired by Novartis as part of the oncology portfolio of UK pharma major GlaxoSmithKline (LSE: GSK), in a $16 billion transaction which completed last month (The Pharma Letter March 2).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical